Review Article | Discussion of current insights to Long-COVID and associated research efforts
The CRO has published a Review article discussing the current knowledge on Long-COVID and the efforts by the pharmaceutical industry, medical device companies as well as academic research to develop efficient and safe medicines to prevent or treat Long-COVID.
As of 7th June 2023 the World Health Organization reported over 767 million confirmed cases of COVID-19. Although most people recover from COVID-19 within a few weeks, about 10% of them develop a complex of long-lasting disabling symptoms called Long-COVID beyond 6 months from infection. Thus, more than 76 million individuals are currently affected worldwide by Long-COVID conditions expected to result in a significant global health and socioeconomic burden.
In this Review article we discuss the current knowledge on Long-COVID including the symptom complex, predictors and supposed pathogenic mechanisms. We describe how the pharmaceutical industry, medical device companies as well as academic research, including the Charité Universitätsmedizin Berlin and Charité Research Organisation GmbH, are now increasing their efforts to develop efficient and safe medicines/therapeutic interventions to treat this burdensome disease.